Suppr超能文献

甘露聚糖结合凝集素相关丝氨酸蛋白酶-2(一种结直肠癌的预后标志物)术前和术后血清水平。

Pre- and postoperative levels in serum of mannan-binding lectin associated serine protease-2 -a prognostic marker in colorectal cancer.

作者信息

Ytting Henriette, Christensen Ib Jarle, Thiel Steffen, Jensenius Jens Christian, Nielsen Hans Jørgen

机构信息

Department of Surgical Gastroenterology, Hvidovre University Hospital, Kettegaard Allé 30, 2650 Hvidovre, Denmark.

出版信息

Hum Immunol. 2008 Jul;69(7):414-20. doi: 10.1016/j.humimm.2008.05.005. Epub 2008 Jun 11.

Abstract

Mannan-binding lectin-associated serine protease-2 (MASP-2) is the initiating enzyme of the lectin pathway of complement activation. High preoperative serum levels of MASP-2 are associated with recurrence and poor survival in patients with colorectal cancer (CRC). In this study we investigate the prognostic role of MASP-2 in patients curatively resected for primary CRC. Serum concentrations of MASP-2 were determined in 281 patients prior to surgery and 7 months postoperatively using a time-resolved immunofluorometric assay. End points were recurrent cancer and death within a median follow-up time of 7.9 years. The correlation between pre- and postoperative levels was 0.49. High postoperative levels of MASP-2 were significantly associated with poor survival [p = 0.04; hazard ratio (HR) = 1.35; 95% confidence interval (CI), 1.02-1.80] and recurrence (p = 0.01, HR = 1.6, 95% CI, 1.1-1.6). The inclusion of age, gender, tumor localization, and Dukes stage in multivariate analysis demonstrated that high MASP-2 levels were independently predictive of survival (p = 0.01; HR = 1.5, 95% CI, 1.1-2.0) and recurrence (p = 0.01, HR = 1.6; 95% CI, 1.1-2.4). Combining pre- and postoperative MASP-2 levels did not improve the prediction of survival/recurrence. High postoperative levels of MASP-2 are associated with poor prognosis in patients curatively resected for CRC. A change of the MASP-2 level from preoperative levels was not, per se, predictive of recurrent disease or survival.

摘要

甘露聚糖结合凝集素相关丝氨酸蛋白酶2(MASP-2)是补体激活凝集素途径的起始酶。术前血清MASP-2水平升高与结直肠癌(CRC)患者的复发及不良生存相关。在本研究中,我们调查了MASP-2在接受原发性CRC根治性切除患者中的预后作用。采用时间分辨免疫荧光分析法测定了281例患者术前及术后7个月时的血清MASP-2浓度。终点指标为在中位随访时间7.9年内的癌症复发和死亡情况。术前和术后水平的相关性为0.49。术后MASP-2水平升高与不良生存显著相关[p = 0.04;风险比(HR)= 1.35;95%置信区间(CI),1.02 - 1.80]及复发相关(p = 0.01,HR = 1.6,95% CI,1.1 - 1.6)。多因素分析纳入年龄、性别、肿瘤定位和Dukes分期后显示,MASP-2水平升高可独立预测生存(p = 0.01;HR = 1.5,95% CI,1.1 - 2.0)和复发(p = 0.01,HR = 1.6;95% CI,1.1 - 2.4)。联合术前和术后MASP-2水平并不能改善对生存/复发的预测。术后MASP-2水平升高与接受CRC根治性切除患者的不良预后相关。MASP-2水平相对于术前水平的变化本身并不能预测疾病复发或生存情况。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验